Plasminogen Activator Inhibitor 1 Pipeline Review, H2 2019
Summary
According to the recently published report 'Plasminogen Activator Inhibitor 1 Pipeline Review, H2 2019'; Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 pipeline Target constitutes close to 12 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 Plasminogen activator inhibitor1 PAI1 also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI1 is a risk factor for thrombosis and atherosclerosis. PAI1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI1 inhibits the activity of matrix metalloproteinases important role in invasion of malignant cells across the basal lamina.
The report 'Plasminogen Activator Inhibitor 1 Pipeline Review, H2 2019' outlays comprehensive information on the Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 7 molecules, respectively. Report covers products from therapy areas Cardiovascular, Oncology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Respiratory, Immunology, Genetic Disorders, Metabolic Disorders and Undisclosed which include indications Arterial Thrombosis, Idiopathic Pulmonary Fibrosis, Non Alcoholic Fatty Liver Disease NAFLD, Renal Failure, Alpha1 Antitrypsin Deficiency A1AD, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Emphysema, Focal Segmental Glomerulosclerosis FSGS, Glioblastoma Multiforme GBM, Graft Versus Host Disease GVHD, Hepatic VenoOcclusive Disease, Inflammatory Bowel Disease, Interstitial Lung Fibrosis, Metastatic Lung Cancer, Multiple Sclerosis, Neuromyelitis Optica Devic's Syndrome, Neurotoxicity Syndromes, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Solid Tumor, Stroke, Systemic Sclerosis Scleroderma, Thromboembolism, Thrombosis, Thrombotic Microangiopathy, Unspecified and Venous Vein Thrombosis.
Scope
The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1
The report reviews Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 targeted therapeutics and enlists all their major and minor projects
The report assesses Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope